Breaks Categories: News

ThursdayApr 16, 2020 9:21 am

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Names New Member to Special Advisory Committee

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, this morning announced the appointment of the former President of Red Bull Canada, Mr. Jim Bailey, to its Special Advisory Committee. Bailey will support in the marketing, distribution and commercialization of Champignon’s Novoformulations-branded novel delivery systems targeting the pharmaceutical, nutraceutical and psychedelic medicine industries. “I am very excited to be part of a company that is leading the way in finding alternative solutions to…

Continue Reading

TuesdayApr 14, 2020 10:34 am

CannabisNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Enters Letter of Intent with Quebec’s SQDC

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium, certified-organic cannabis, today announced that it has signed a letter of intent with the Société québécoise du cannabis ("SQDC") ahead of the upcoming launch of its lineup of teas made with only certified organic ingredients. "Entering the Quebec market is an important milestone for TGOD as we continue ramping up sales and production volumes," Brian Athaide, CEO of TGOD, stated in the news release.  "Our teas leverage the same fast-acting technology used for TGOD Infusers, and a proprietary know-how, which eliminates the need to use sugar…

Continue Reading

MondayApr 13, 2020 10:26 am

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Enters Definitive Agreement to Acquire AltMed Capital Corp.

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to accelerate its advancements within the psychedelic medicine arena. On Thursday, Champignon Brands announced its plans to acquire a leading Canadian ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer (the “Transaction”) and has entered into a definitive agreement (the “Agreement”) to acquire 100% of AltMed Capital Corp. (“AltMed”). “Founded and operated by Dr. McIntyre, the CRTCE has the human capital…

Continue Reading

TuesdayApr 07, 2020 10:03 am

CannabisNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) Announces Receipt of Notices of Default from MXY Holdings LLC

Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) today announced its receipt of a notice of default from MXY Holdings LLC (“Moxie”) related to a US$5,000,000 note for which it provided a guaranty as a condition to Moxie extending the loan to GGB Beauty LLC on July 8, 2019. According to the update, the note had a January 31, 2020, maturity date and the parties were unable to reach agreement as to an extension. In conjunction, the company also received notice that its obligations with respect to the previously announced US$4,000,000 termination fee owed to Moxie would also be accelerated and…

Continue Reading

FridayApr 03, 2020 11:54 am

CannabisNewsBreaks – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) Announces Partial Debenture Repurchase

VIVO Cannabis (TSX: VIVO) (OTCQX: VVCIF) today announced that it has re-purchased for cancellation certain of its outstanding 6% unsecured convertible debentures in the aggregate principal amount of $10 million, for a purchase price of $9.3 million (plus accrued and unpaid interest thereon), representing a 7% discount to the face value, pursuant to an agreement with the holder thereof. The company, as a result of the repurchase, now has Debentures in the aggregate principal amount of $24.5 million due February 28, 2021. “As evidenced by our recent financial results, VIVO continues to enjoy a strong cash position,” VIVO's Chief Executive…

Continue Reading

FridayApr 03, 2020 10:45 am

CannabisNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) Announces Consent to Receivership Appointment for CBD Business, Continuation of Cannabis Business in FL, MA and NV

Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) today announced that a special committee of the Board of Directors has concluded the previously announced strategic review process related to the company's cannabidiol (“CBD”) business. As a result, Green Growth Brands has determined that appointment of a receiver is in the best interest of the company and the creditors of the CBD business.  The CBD business is operated by six of the company's subsidiaries: Green Growth Brands LLC, GGB Beauty LLC, GGB Licenses LLC, Green Growth Brands Realty LLC, GGB Kiosks LLC, and GGB GN LLC, each of which will be subject…

Continue Reading

ThursdayApr 02, 2020 9:22 am

CannabisNewsBreaks – Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Completes First Cannabis Shipment to Israel; Provides Corporate Update Regarding COVID-19

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) this morning announced the successful completion of its first international cannabis shipment from Canada into Israel. Supreme Cannabis partnered with Israel's largest producer of medical cannabis and cannabis products, Breath of Life International Ltd. ("BOL Pharma"), to offer Truverra-branded premium medical cannabis to patients in Israel. Additionally, the company provided a corporate update regarding COVID-19, in which it detailed its efforts to mitigate risk and manage disruption to its operations. Per the update, minor external business disruptions including supplier and third-party testing delays have extended the launch dates for 7ACRES' whole…

Continue Reading

TuesdayMar 31, 2020 10:13 am

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Expands Special Advisory Committee with Appointment of University of Toronto Clinical Advisor, Pharmacognosist

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced continued augmentation of its Special Advisory Committee with the addition of key individuals experienced in highly regulated industries primed for rapid growth. To this accord, the Company announced the appointment of Jay Kheita, ACPR, to its Special Advisory Committee, where he will help lead the integration of Champignon’s novel and natural treatment protocols into its existing consumer packaged goods (“CPGs”) portfolio. Khetia…

Continue Reading

TuesdayMar 31, 2020 9:38 am

CannabisNewsBreaks – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) Announces Q4 and Full Year 2019 Results

VIVO Cannabis (TSX: VIVO) (OTCQX: VVCIF) on Monday released its year end and fourth quarter 2019 financial and operating results. Among the highlights, the Company reported a 139% year-over-year increase in revenue, with 7% increase in SG&A expenses, successful launch of initial Cannabis 2.0 products, as well as accelerated growth into Q1 2020. "During the fourth quarter of 2019, VIVO continued to execute on our strategy, recording revenue growth, sustaining top-tier prices for our premium products, and executing a successful launch of Cannabis 2.0 products," VIVO CEO Barry Fishman stated in the news release. "We have maintained a disciplined and…

Continue Reading

MondayMar 30, 2020 11:03 am

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Enters Definitive Agreement to Acquire Tassili Life Sciences Corp.

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a health and wellness company specializing in the formulation of medicinal mushrooms health products and novel delivery platforms for the pharmaceutical and nutraceutical industries, today announced its entry into a definitive agreement to acquire Tassili Life Sciences Corp. Per the update, the move will expand the Company’s preclinical trial pipeline, as well as its aggregation of broad intellectual property (IP) related to the development of novel psychedelics therapeutics and their delivery systems, targeting multiple pathological psychological diseases. Tassili has partnered with a multidisciplinary team of scientists and physicians at the University of…

Continue Reading